Share Name Share Symbol Market Type Share ISIN Share Description
GlaxoSmithKline LSE:GSK London Ordinary Share GB0009252882 ORD 25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +9.00p +0.55% 1,645.50p 1,644.50p 1,645.00p 1,649.50p 1,635.00p 1,636.50p 8,704,939.00 16:35:25
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 27,889.0 1,939.0 18.8 87.5 80,800.53

GlaxoSmithKline Share Discussion Threads

Showing 13876 to 13898 of 13900 messages
Chat Pages: 556  555  554  553  552  551  550  549  548  547  546  545  Older
DateSubjectAuthorDiscuss
21/2/2017
19:25
Nice chart bracke.
tim 3
21/2/2017
18:50
I bought at 1405 and plan to keep these - but I may take out a small s at 1700 as a wee hedge.
toffeeman
21/2/2017
17:30
Well it's going up on this leg, 1715p will be difficult to get through, so could retrace to around 1645p imho but I don't really sell at resistance, just hold and add more on any retrace.
ny boy
21/2/2017
17:21
Toffee Gold star for you. maurillac missed 'sideways'. Worth keeping an eye on the price action if you are thinking of a, I'll say it quietly, short.
bracke
21/2/2017
16:49
Nah it may go up or down or sideways :)
toffeeman
21/2/2017
15:07
so it could go up or down, or up, down and up again ;) m
maurillac
21/2/2017
12:46
Having reached the Median Line (middle green) it's decision time. Best option is 'zoom' through and keep going. Second best is move above ML then drop back for a successful retest. Third best is as second best but test fails to hold. Equal third, fails to break above ML and simply retraces. I suppose I should mention the possibility that the share price simply tracks up along the ML. GSK DAILY
bracke
21/2/2017
12:19
Courtesy of Rowan Dartington: GlaxoSmithKline (GSK.L) Buy Income Risk 3 The Pharmaceuticals company recently announced Final results to December 2016. The results were in line with expectations with Group sales rising +17% to £27.9bn (+5% constant exchange rates), aided by a weak Sterling and growth in new products. In terms of outlook, 2017 Group EPS will depend on the timing and degree of the impact of US generic competition on Glaxo's asthma drug, Advair. Assuming a bearish case for Advair (assumes US Advair sales fall -45% to $1.36bn in 2017), core EPS will be flattish if competition begins mid-year Valuing the Group on a Dec’17 P/E of 14.5x, an 11% discount to the Market. This is good value considering that the Pharmaceutical division should not be impacted significantly by generics for several years post 2017. Total Pharmaceutical sales should be slightly higher in 2020 compared to 2016 due to new products (+£2.2bn to £6bn by 2020) outweighing the decline in US Advair sales (c £1.3bn in total). The two other divisions, Vaccines and Consumer Healthcare, should continue to trade well on the back of the Novartis acquisitions. The Group is trading at a discount to its Global Consumer Healthcare peers who trade on an average P/E of around 20x. The yield of 5% should also offer great protec-tion in these uncertain equity markets. Trump should not impact the pharmaceutical sector too much because competition has worked well in terms of the patent rules and of the strength of the Pharmacy Benefit Managers.
minerve
21/2/2017
09:00
Onwards to 1715p resistance, within a rising trend channel
ny boy
20/2/2017
00:00
No, what is it, buy/sell?
ny boy
17/2/2017
21:18
Hi there, did anybody notice the 1,351,062 trade at 16.39
somptinglad
17/2/2017
17:59
With the £ heading lower, who knows, it's possible, it's just one of a few that have been earmarked before, the low £ allows a pedestrian to make a blow out offer, therefore likely to meet approval of shareholders..interesting times ahead.
ny boy
17/2/2017
17:40
Unilever today, will glaxo be next...?
spoole5
17/2/2017
09:47
Figures, also defensive qualities when the markets correct. Sterling’s collapse makes GlaxoSmithKline plc an attractive takeover target
ny boy
17/2/2017
09:44
17th feb Jefferies buy tp 1800p up from 1780p
philanderer
17/2/2017
07:55
Tks, I must if been thinking of another stock.
ny boy
17/2/2017
07:41
XD,Next Thursday 23th Feb 23p per share.Paid on Thursday 13th of April.
garycook
17/2/2017
07:38
Isn't it ex div today?
ny boy
16/2/2017
15:40
flying today. Next stop £17, or maybe a pause at 16.50?
tim 3
16/2/2017
12:18
Breaking higher
ny boy
16/2/2017
11:46
NY Boy - Seems to be doing well, I'm happy with the ViiV statement, good start for new CEO, but things can change haha.
losos
16/2/2017
08:17
Broken through 1592p resistance, closes above this level, suggest a crack at next resistance level 1715p this quarter.
ny boy
16/2/2017
08:05
Breakout coming?
ny boy
Chat Pages: 556  555  554  553  552  551  550  549  548  547  546  545  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:42 V: D:20170221 23:27:32